← Back to Clinical Trials
Recruiting NCT07416279

NCT07416279 Can Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07416279
Status Recruiting
Phase
Sponsor King's College London
Condition HFpEF - Heart Failure With Preserved Ejection Fraction
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2026-02
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 81 Years
Study Type INTERVENTIONAL
Interventions
Contrast Echocardiography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2026-02 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to investigate if ultrasound contrast agents can be used to estimate filling pressures inside the heart in patients with suspected heart disease. The main questions it aims to answer are: * Is there a strong correlation between the contrast signal and filling pressures inside the heart? * What is the calibration approach to convert the contrast signal from dB to a measure of pressure in mmHg? Researchers will compare the contrast signal with reference pressures measured using a catheter to see if it can be used to quantify filling pressures inside the heart. Participants will: * Be exposed to a small amount of additional ionising radiation to guide a catheter in position inside the heart for reference pressures * Receive an ultrasound contrast agent at the clinically recommended dose and in line with clinical guidelines, via an intravenous line in their arm * Undergo contrast echocardiography - ultrasound scan of their heart with contrast * Undergo standard echocardiography - ultrasound scan of their heart without contrast

Eligibility Criteria

Inclusion Criteria: * Participant is willing and able to give informed consent to participate in the study * Patients who require a cardiac catheterisation procedure as part of their standard medical care * Good acoustic windows for echocardiography when lying flat on their back Exclusion Criteria: * Known previous allergy to SonoVue, used in ultrasound contrast scans * Known allergy to any of the components of SonoVue microbubbles, for example, sulphur hexafluoride or polyethylene glycol (PEG), also known as macrogol, which is in bowel preparations used during colonoscopy and certain laxatives * A hole in their heart that lets blood flow from the right side to the left, skipping the lungs * Very high blood pressure in the arteries of the lungs (severe pulmonary hypertension) * Uncontrolled high blood pressure (hypertension) * Adult respiratory distress syndrome (ARDS; where severe lung inflammation prevents enough oxygen from reaching the body) * Current use of the medicine dobutamine (used to treat heart failure), or have been advised not to take dobutamine * Moderate to severe heart valve disease that could affect the catheter measurements * Recent acute coronary syndrome or unstable ischaemic cardiac disease, where blood flow to the heart muscle is reduced * Pregnant or may be pregnant * Participation in a clinical trial of a medicine within the past four months, to avoid any possible interactions with SonoVue * Participating in other research that would prolong their cardiac catheterisation procedure, to ensure that the overall process does not become too tiring or burdensome

Contact & Investigator

Central Contact

Amanda Nio, PhD

✉ amanda.nio@kcl.ac.uk

📞 +44 (0)20 7836 5454

Frequently Asked Questions

Who can join the NCT07416279 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 81 Years, studying HFpEF - Heart Failure With Preserved Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07416279 currently recruiting?

Yes, NCT07416279 is actively recruiting participants. Contact the research team at amanda.nio@kcl.ac.uk for enrollment information.

Where is the NCT07416279 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT07416279 clinical trial?

NCT07416279 is sponsored by King's College London. The trial plans to enroll 10 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology